Nutrition 21s Diachrome® Effective in Reducing CVD RiskFactors

Nutrition 21s Diachrome® Effective in Reducing CVD RiskFactors

UNIVERSAL CITY, Calif.Arecent randomized, double blind, placebo-controlled study found a significantcorrelation between increased urinary chromium levelsa measure of chromiumabsorptionand reductions in cardiovascular disease (CVD) risk factors,including total cholesterol, triglycerides, low-density lipoprotein (LDL)cholesterol and lipid ratios in people with Type II diabetes.The data werepresented at the 2nd World Congress on Insulin Resistance Syndrome (IRS).

Scientists evaluated 36 Type II diabetics over a 30-dayperiod. The significant reduction in CVD risk factors was seen in studyparticipants given Diachrome®, (a combination of 600 mcg of chromium aschromium picolinate and 2 mg biotin) supplementation daily. The group takingDiachrome also had significantly improved glycemic control, as measured by areduction in blood glucose levels after consuming a beverage that contained 75 gcarbohydrates.

We are pleased to have the opportunity to present ourlatest research on chromium to the leading medical experts concerned about thegrowing epidemic of insulin resistance, said Gail Montgomery, president andchief executive officer of Purchase, N.Y.- based Nutrition 21(www.nutrition21.com), which commissioned the study. As Nutrition 21sresearch program unfolds, we expect to confirm the role of chromium picolinateas a safe and effective adjunct nutritional therapy for the many healthconditions linked to impaired insulin function.